VivoSeq
Other

Ovarian Hyperstimulation Syndrome

19

Pipeline Programs↗

2

Active Trials↗

9

Companies Involved↗

Ovarian Hyperstimulation Syndrome is an emerging landscape with 19 programs across 9 companies. The most active players are EMD Serono, Eli Lilly, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. 3 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

29/100

Completion Rate

82/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono logo

EMD Serono

2 programs

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3G

Guizhou Bailing Group Pharmaceutical Co Ltd

1 program

Phase 3Merck & Co. logo

Merck & Co.

1 program

Phase 3Pfizer logo

Pfizer

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

96%

Small molecule

23 of 24 classified programs — the dominant modality here.

4%ALL OTHERSPeptide14%

Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 100% of 24 pipeline programs.

Analysis

Trial Status

26

clinical trials

Completed14 · 54%
Unknown status7 · 27%
Recruiting2 · 8%
Withdrawn2 · 8%
Terminated1 · 4%

Clinical Trials

Trial Activity

26 trials

Ovarian Hyperstimulation Syndrome Prevention
Recruiting·—·N/A·NCT06739759·300 enrolled
Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome
Recruiting·TTanta University·Phase 2·NCT07043322·150 enrolled
Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response
Completed·GGanin Fertility Center·Phase 2·NCT04351126·107 enrolled
The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors
Completed·VVirginia Center for Reproductive Medicine·N/A·NCT00867659·20 enrolled
Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention
Completed·—·Phase 3·NCT03473613·230 enrolled
Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome
Completed·—·Phase 2·NCT02875587·170 enrolled
Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention
Completed·HHospital de Cruces·Phase 1·NCT01530490·80 enrolled
Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome
Completed·—·Phase 2/3·NCT02271360·200 enrolled
Calcium for Prevention of Ovarian Hyperstimulation Syndrome
Completed·—·Phase 3·NCT01427335·200 enrolled
Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome
Completed·—·Phase 2/3·NCT02134249·200 enrolled
Ovarian Hyperstimulation Syndrome and Cabergoline
Completed·EEtlik Zubeyde Hanim Womens' Health and Teaching Hospital·N/A·NCT01569256·40 enrolled
GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome
Completed·IInstituto Valenciano de Infertilidad, IVI VALENCIA·Phase 3·NCT01268761·100 enrolled
Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers
Completed·KKK Women's and Children's Hospital·Phase 3·NCT01535859·46 enrolled
Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome
Completed·IInstituto Valenciano de Infertilidad, IVI VALENCIA·Phase 2·NCT00665041·30 enrolled
Calcium Dobesilate Versus Coasting for Prevention of Ovarian Hyperstimulation Syndrome
Completed·Kkhalid abd aziz mohamed·Phase 2/3·NCT02290002·200 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)